JY
ATOS icon

Jeff Yass’s Atossa Therapeutics ATOS Stock Holding History

Jeff Yass’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8K Buy
+11,300
New +$51.5K ﹤0.01% 13027
2025
Q4 		– Sell
-1,800
Closed -$23.5K – 12298
2025
Q3 		$23.5K Buy
+1,800
New +$22.2K ﹤0.01% 12024
2024
Q4 		– Sell
-24,047
Closed -$548K – 12149
2024
Q3 		$548K Buy
24,047
+2,687
+13% +$54.2K ﹤0.01% 8242
2024
Q2 		$381K Buy
21,360
+18,640
+685% +$412K ﹤0.01% 8912
2024
Q1 		$73.4K Sell
2,720
-1,800
-40% -$28.9K ﹤0.01% 11376
2023
Q4 		$59.7K Buy
4,520
+3,280
+265% +$35.4K ﹤0.01% 11642
2023
Q3 		$13.8K Sell
1,240
-3,527
-74% -$51.2K ﹤0.01% 11677
2023
Q2 		$90.1K Buy
4,767
+1,900
+66% +$23K ﹤0.01% 11026
2023
Q1 		$31K Sell
2,867
-9,673
-77% -$108K ﹤0.01% 11897
2022
Q4 		$99.7K Sell
12,540
-7,173
-36% -$82.4K ﹤0.01% 10963
2022
Q3 		$245K Sell
19,713
-714
-3% -$10.4K ﹤0.01% 10312
2022
Q2 		$334K Buy
20,427
+1,974
+11% +$31.1K ﹤0.01% 9278
2022
Q1 		$346K Sell
18,453
-18,434
-50% -$374K ﹤0.01% 9913
2021
Q4 		$885K Sell
36,887
-64,546
-64% -$2.36M ﹤0.01% 7606
2021
Q3 		$4.96M Buy
101,433
+880
+0.9% +$51.2K ﹤0.01% 3976
2021
Q2 		$9.53M Buy
100,553
+39,193
+64% +$2.07M ﹤0.01% 2992
2021
Q1 		$1.94M Buy
61,360
+58,473
+2,025% +$2.14M ﹤0.01% 6005
2020
Q4 		$41K Buy
+2,887
New +$66.8K ﹤0.01% 10792

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's ATOS Position: Q2 2026 in Review

Jeff Yass opened a new position in Atossa Therapeutics (ATOS) in Q2 2026: 15,574 shares worth $30.1K. The stake represents ﹤0.01% of the portfolio and ranks #12959 among its holdings. This is a return to the name: Jeff Yass previously reported a position in ATOS as recently as Q4 2025.

Jeff Yass first reported a position in ATOS in Q1 2018 and has held it in 24 quarters since. The position peaked at $16.4M in Q2 2021. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Jeff Yass held 15,574 shares of Atossa Therapeutics worth $30.1K as of Q2 2026.
  • Atossa Therapeutics was a new Jeff Yass position in Q2 2026.
  • Atossa Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12959 holding.
  • Jeff Yass first reported a position in Atossa Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • Jeff Yass's Atossa Therapeutics position peaked at $16.4M in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.